Edition:
India

People: Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

18.90USD
17 Oct 2019
Change (% chg)

-- (--)
Prev Close
$18.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
469,059
52-wk High
$18.99
52-wk Low
$8.39

Lavelle, Erin 

Ms. Erin Lavelle is Chief Operating Officer of the Company. Ms. Lavelle has served as our Chief Operating Officer since April 2018. From October 2017 to March 2018, Ms. Lavelle served as the General Manager of the Taiwan affiliate of Amgen Inc., a biopharmaceutical company. From June 2016 to September 2017, Ms. Lavelle served as Executive Director, Japan and Asia-Pacific Commercial Excellence and Digital Health at Amgen. From July 2003 to June 2016, Ms. Lavelle served in roles of increasing responsibility at Amgen, including as Executive Director in the areas of Global Marketing; Global Commercial Finance; and Strategy and Corporate Development. She began her career in 1998 as an investment banker in the healthcare group at Merrill Lynch & Co. Ms. Lavelle holds a B.A. in Economics from Yale University.

Basic Compensation

Total Annual Compensation, USD 283,590
Restricted Stock Award, USD 268,502
Long-Term Incentive Plans, USD 128,160
All Other, USD 3,000,140
Fiscal Year Total, USD 3,680,390

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Robert Azelby

10,130,800

Carlos Campoy

1,844,370

Erin Lavelle

3,680,390

James Bucher

1,961,540

Randal Hassler

4,217,190

Nadia Dac

--
As Of  31 Dec 2018